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Abstract
The genital mycoplasmas are a unique group of inherently antibiotic-resistant sexually transmitted bacteria, often associated with
non-gonococcal urethritis and bacterial vaginosis. The MYCOWELL D-ONE is a culture-based assay that aims to detect these
organisms whilst concurrently screening them for antibiotic resistance. Urine and/or swabs from 856 informed and consented
participants attendingWelsh sexual health clinics were subjected toMYCOWELLD-ONE analysis, alongside qPCR and culture
titration methodologies to determine sensitivity, specificity, PPV, NPV and accuracy. Resistance was confirmed by CLSI-
compliant susceptibility testing and genetic mechanisms determined. The MYCO WELL D-ONE displayed a sensitivity and
specificity of 91.98% and 96.44% for the detection of Ureaplasma spp., with sensitivity and specificity values of 78.23% and
98.84% for Mycoplasma hominis, compared with qPCR. Swabs harboured significantly greater bacterial loads than urine
samples for both Ureaplasma spp. and M. hominis. Levofloxacin resistance rates, mediated by Ser83Leu mutation in ParC,
forUreaplasma spp. were 0.54%. Tetracycline resistance rates, mediated by tet(M), were 0.54% and 2% forUreaplasma spp. and
M. hominis, respectively; sequence analysis of tet(M)-positive Ureaplasma spp. and M. hominis strains isolated from a single
individual confirmed separate resistance gene origins. The MYCO WELL D-ONE is a sensitive and specific assay for the
detection of Ureaplasma spp. and M. hominis in genitourinary medicine samples, facilitating the accurate detection of these
organisms within low-technology environments. While good for antibiotic resistance screening, accurate confirmation by MIC
determination or molecular methods are required, and more optimally performed on urine samples.
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Introduction
Ureaplasma spp. (Ureaplasma parvum and Ureaplasma
urealyticum) and Mycoplasma hominis are often colloquially
termed the ‘genital mycoplasmas’ (alongside Mycoplasma
genitalium) due to their isolation from the human urogenital
tract. All of the unique classMollicutes, named from the Latin
mollis (meaning soft) and cutis (meaning skin), lack a cell wall
[1]. This idiosyncratic physiology, directly related to their re-
duced genome and subsequent limited biosynthetic capacity
results in an inherent resistance to several groups of antibi-
otics, the β-lactams (including penicillins and cephalospo-
rins), the glycopeptides, sulphonamides and trimethoprim [2,
3]. Consequently, treatment options for these unique bacteria
are limited, restricted to four classes of antibiotics:
fluoroquinolones, chloramphenicol, tetracyclines and
macrolides. Further restrictions apply to pregnant females
and neonates as administering all classes besides macrolides
are contraindicated. Furthermore, M. hominis possesses a
species-specific resistance to 14- and 15-membered ring
macrolides, mediated by a G2057A transition in its 23S
rRNA sequence [4], but remain susceptible to 16-membered
ring macrolides such as Josamycin.
Though not recognised as equivalent to chlamydia,
gonorrhoea or Mycoplasma genitalium as pathogens, these
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innately resistant bacteria are implicated in several urogenital
pathologies, with Ureaplasma spp. being the only infectious
agent in 10–20% of non-gonococcal urethritis (NGU) cases
[5], important as currently 45% of NGU are categorised as
idiopathic [6]. In females, Ureaplasma spp. has been reported
as associated with non-specific cervicitis (NSC) [7], endome-
tritis [8] and preterm birth [9]. Whereas M. hominis is impli-
cated in bacterial vaginosis (BV) [10] and pelvic inflammato-
ry disease (PID) [11]. However, despite mounting evidence
associating these organisms with disease, much controversy
still surrounds them, owed to their isolation from seemingly
healthy asymptomatic populations. However, although
Chlamydia trachomatis presents as asymptomatic in most
women, genital tract chlamydial infections are well accepted
as the leading cause of PID, tubal factor infertility and ectopic
pregnancy [12]. The dichotomy encompassing their classifi-
cation as either ‘commensal’ or ‘pathogen’ means the recom-
mendation to routinely screen for and treat these organisms is
currently withheld pending more robust, better-designed stud-
ies that unequivocally solidify their role in disease [13].
Historically, studies presenting conflicting conclusions on
the pathogenicity of Ureaplasma spp. and M. hominis failed
to separate Ureaplasma into the 2 separate species or deter-
mine bacterial load, factors shown to influence the pathogenic
potential of genital Mollicutes infection [14–16].
Consequently, researchers now suggest a risk-based treatment
approach toward Ureaplasma spp. infection be taken—one
considering Ureaplasma species, load and known risk factors
(age, number of sexual partners etc.)—in cases of symptom-
atic NGU, devoid of more accepted etiological agents (i.e.
chlamydia, gonorrhoea, M. genitalium, etc.) [17].
Traditional culture-based detection and enumeration
methods for these organisms are complicated by their fastidi-
ous growth requirements and inability to grow to visual tur-
bidity. Possessing a urea-metabolising enzyme, Ureaplasma
spp. are unique among mycoplasmas, which are typically
characterised by the substrate utilised for ATP generation:
arginine or glucose (arginine in the case of M. hominis) [18].
Culture-based detection techniques employ Ureaplasma spp.
ability to produce ammonium ions and increase pH through
urea hydrolysis. Similarly, the arginine-dihydolase pathway
produces ammonium ions and raises pH during the broth cul-
ture of M. hominis. Bespoke media exploit these substrate-
specific pathways for detection, visualized through the addi-
tion of a pH indicator (typically phenol red) and increased pH
from bacterial growth being visualised by a non-turbid yellow
to cerise-red colour change in the presence of beta-lactam
antibiotics. More sensitive and specific approaches for the
detection of these fastidious organisms are available through
qPCR, which should be viewed as the ‘gold-standard’ detec-
tion method [19] which permits Ureaplasma speciation.
Though more sensitive, qPCR-based approaches remain un-
economical and impractical for genitalMollicutes detection in
low-resource laboratories with low to moderate sample vol-
umes, where culture-based assays are better-suited. A key ad-
vantage of culture-based approaches is that they provide a
viable isolate on which antimicrobial susceptibility testing
(AST) can be performed. In commercially available diagnos-
tic assays, this is done simultaneously alongside detection,
through supplementing wells containing specific growth me-
dium with breakpoint concentrations of antibiotics. Several
commercially available detection kits have been utilised for
detection and antimicrobial resistance reporting of
Ureaplasma spp. and M. hominis: MYCOFAST revolutioN
(ELiTech Diagnostic, France), Mycoplasma Duo and
Mycoplasma SIR (Bio-Rad; Watford, U.K),Mycoplasma sys-
tem plus (Liofilchem, Italy), Mycoplasma IST2 (Biomerieux,
France). However, these assays fail to utilise CLSI (Clinical
Laboratory Standards Institute) set international threshold
concentrations of a standardised antibiotic panel, often leading
to inappropriate and unvalidated reporting of resistance data
[20, 21]. Commercial assays also often fail to take into ac-
count the quantification of the bacterial inoculum tested, set
by CLSI guidelines as 104–105 colour changing units/mL
(CCU/mL), as higher bacterial loads have a demonstrable pro-
pensity to produce false positive results [22]. Alongside this,
many kits do not separate Ureaplasma spp. and M. hominis
coinfection, which complicates interpreting the AST, leading
to the over-reporting of macrolide resistance due to M.
hominis intrinsic macrolide resistance [20, 23]. In response,
CPM SAS (Rome, Italy) developed the MYCO WELL D-
ONE—the first commercially available assay that offers
CLSI-compliant antibiotic breakpoints for AST of
Ureaplasma spp. and M. hominis separately.
The present investigation was carried out to determine the
sensitivity and specificity of the MYCO WELL D-ONE
against gold-standard qPCR detection methods alongside cul-
ture detection in specialist culture media and CLSI-compliant
broth microdilution confirmation of detected antimicrobial
resistance.
Materials and methods
Participant samples
Urine and/or swabs (urethral, endocervical or high-vaginal)
were collected from informed and consented participants—
under ethical approval (IRAS 230693)—from October 2017
to October 2018 attending Welsh sexual health walk-in clinics
held at Dewi Sant hospital (Pontypridd), Keir Hardie Health
Park (Merthyr Tydfil), or Ysbyty Cwm Cynon (Mountain
Ash). A total of 983 samples were collected from 856 patients;
526 female patients, of which 122 provided both urine and
endocervical swabs; 335 males, of which 5 provided both
urine and urethral swabs.
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Sample processing protocol
For qPCR analysis, participant’s urine samples were proc-
essed as follows: 2 mL of urine was transferred to a sterile
2 mL Eppendorf tube and centrifuged at 15,000×g for 20 min,
supernatant removed and pellet frozen at − 86 °C until extrac-
tion of genomic DNA using the QIAGEN QIACube automat-
ed extraction system (DNeasy Blood & Tissue kit, bacterial
pellet protocol with RNase treatment; elution into 100 μL
molecular grade water). Participant’s swab samples were proc-
essed as follows: Copan Rayon swab samples were either
taken by the clinician (endocervical) or self-taken by the par-
ticipant (high vaginal), the swab was then suspended in 10mL
sterile saline (CPM S.A.S.), 2 mL of the swab suspension was
centrifuged and processed for DNA extraction as for urine
above. DNA extracts were stored at − 86 °C until batch
analysed by quantitative PCR. Concurrently, the MYCO
WELL D-ONE assay (purchased from CPM S.A.S., Rome,
Italy) was processed as per manufacturer’s instructions.
Briefly, 150 μL of swab- (swab resuspended in 10 mL saline)
or urine-inoculated saline (200 μL urine added to 10 mL sa-
line) was transferred to each well, topped with two drops of
paraffin oil to create an anaerobic environment and stop evap-
oration and incubated at 37 °C and ambient CO2.
Additionally, alongside the MYCOWELL D-ONE and
qPCR assays, a culture titration assay was implemented to
concurrently detect and determine the bacterial load of each
swab/urine-inoculated saline sample. The culture titration as-
say for Ureaplasma has been previously described [22] and
was modified to include the additional titration ofM. hominis
in parallel using M. hominis-specific medium (MHSM) pur-
chased from CPM SAS (Rome, Italy). Briefly, titration and
breakpoint screening in antibiotics were set up in sterile 96-
well flat-bottomed microtitre plates receiving 10 μL of
sample-inoculated sterile saline containing 90 μL of
Ureaplasma or M. hominis-specific medium prior to 1:10 di-
lution series in the same medium to a final 10−7dilution.
Uninoculated medium was included in parallel and acted as
a negative control for each serial dilution; the plates were then
sealed with transparent adhesive sealing tape (Elkay:
Basingstoke, United Kingdom), and were incubated at 37 °C
and ambient CO2. Alongside this culture titration methodolo-
gy, 20 μL of undiluted urine was pipetted into 180 μL USM
and MHSM and incubated at 37 °C and read at various inter-
vals up to 72 h post-incubation; this latter method was includ-
ed because 10 μL of 1:500 diluted urine in sterile saline was
15-fold less than the amount inoculated into the MYCO
WELL D-ONE and has an overall limit of detection of 103
CCU per mL. Finally, 5 μL of inoculated sterile saline solu-
tion was pipetted directly onto the surface of US1 agar
(Mycoplasma Experience) and incubated at 37 °C and ambi-
ent CO2. Positives were determined through the presence of a
classic ‘fried-egg’ morphology under light microscopy forM.
hominis, and red pH colour change in the media with tiny
granular Ureaplasma colonies.
Molecular analysis
BioRad Laboratories (Watford, UK) CFX96 TouchReal-Time
PCR thermocycler and BioRad Maestro software was used to
run the assays. SsoAdvanced Universal Probes Supermix for
hydrolysis probes (BioRad Laboratories) and 96-well plates
and optical clear adhesive seals (BioRad Laboratories) were
used. Total volume of each reaction was 20 μL, comprised of
the following: 10 μL 2x mastermix, 0.25 pmol/μL
Ureaplasma parvum forward primer, 0.25 pmol/μL
Ureaplasma parvum reverse primer, 0.01 pmol/μL
Ureaplasma parvum probe; 0.25 pmol/μL Ureaplasma
urealyticum forward primer, 0.25 pmol/μL Ureaplasma
urealyticum reverse primer, 0.01 pmol/μL Ureaplasma
urealyticum probe; 0.25 pmol/μL Mycoplasma hominis for-
ward primer, 0.25 pmol/μL Mycoplasma hominis reverse
primer, 0.01 pmol/μL Mycoplasma hominis probe, with the
remainder molecular grade water. Genomic copy equivalents
were determined against a 6-point standard curve (106–101
copies) of diluted plasmid containing concatamers of the
primer and probe targets separated by 30 bp intervening se-
quences (synthesized by GenScript) and accurately quantified
by Life Technologies Qubit fluorometer DNA quantification
system. Primers and Taqman hydrolysis probes for
Ureaplasma parvum and Ureaplasma urealyticum were pre-
viously clinically validated [24] as were primers and Taqman
hydrolysis probes for Mycoplasma hominis [25]. Bio-Rad
CFX96 cycling conditions were as follows: initial activation
and denaturation 95 °C for 5 min, next 45 cycles of 95 °C for
15 s and 60 °C for 15 s. Readings were acquired in between
cycles on channels FAM, HEX, ROX and CY5. Data was
analysed on Bio-Rad CFXMaestro software. Presence of am-
plification inhibitors were assessed using QIAGEN
Quantinova as per manufacturer’s instructions. Primers and
probes are listed in Supplementary Table 1.
CLSI-compliant break-point antimicrobial susceptibil-
ity testing
Analysis of putative resistant isolates was conducted in accor-
dance with CLSI M43A(21) using a previously published
methodology for breakpoint analysis forUreaplasma spp. iso-
lates [22]. The method was modified to include additional
antibiotics, alongside utilising MHSM for the breakpoint
screening of M. hominis isolates. Isolates were screened
against the CLSI guideline concentrations of antibiotic.
Isolates were only screened against antibiotics if they had
shown supposed resistance to that antibiotic on the MYCO
WELL D-ONE assay. All antibiotics were purchased from
Sigma-Aldrich (Dorset, UK) and supplied as or reconstituted
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to 1 mg/mL stock solutions, prior to further dilution in the
appropriate media (USM/MHSM) to achieve CLSI-
compliant concentrations for AST.
Whole genome sequencing
All isolates confirmed to be antibiotic resistant by CLSI-
compliant methods were scaled up to 500 mL culture, pelleted
at 13,000×g for 3 h and DNA extracted using the QIAcube
and QIAGEN reagents for Gram-negative protocol described
above. Following extraction of DNA, Qubit 4.0 (Life
Technologies) fluorometric analysis verified a sufficient con-
centration of DNA was isolated (1–8 ng/μL). Briefly, whole
genome sequencing was performed using a Nextera XT li-
brary preparation and sequenced with a V3 chemistry on an
Illumina MiSeq platform. The bioinformatics pipeline was
comprised of 3 main processes; (1) QC pipeline to validate
and trim the raw sequence reads: FastQC and Trimgalore [26,
27]; (2) whole genome assembly and mapping: Flash,
SPAdes, BWA, pilon and quast [28–32]; (3) whole genome
annotation and profiling of genetic determinants using a com-
bination of available software (using both fastq and de novo
assembled reads): prokka, NCBI BLAST, kmerfinder, CARD,
srst2, ARG-ANNOT and VFDB [33–39]. Assembled contigs
were further analysed utilising Geneious sequence analysis
software (BioMatters Ltd., New Zealand) and aligned and
assessed against antibiotic susceptible reference sequences
for the identification of mobile genetic elements or point
mutations.
Statistical analysis
All statistical analyses were performed using GraphPad Prism
version 7 (GraphPad Software). Significance was only attrib-
uted to comparisons where P value < 0.05.
Results
Assay sensitivity and specificity
The multiplex qPCR implemented for the detection of
Ureaplasma spp. and M. hominis infections was utilised as
the ‘gold standard’ reference methodology to determine the
sensitivity and specificity of the MYCOWELLD-ONE assay
detecting these organisms (Tables 1 and 2). For the detection
of Ureaplasma spp. from 983 samples, 413 qPCR positive
samples, 515 qPCR negative samples, 19 false positive
(qPCR negative, MYCO WELL D-ONE positive) samples
and 26 false negative (qPCR positive, MYCO WELL D-
ONE negative) samples were identified, when comparing
MYCO WELL D-ONE data with that of qPCR. Utilising
these data, the sensitivity and specificity for the detection of
Ureaplasma infection for the MYCO WELL D-ONE is cal-
culated to be 91.98% and 96.44%, respectively. The positive
predictive value (PPV) and negative predictive value (NPV)
of the MYCO WELL D-ONE to determine Ureaplasma in-
fection was 95.6% and 93.47%, respectively, with an accuracy
of 94.4%. For the detection of M. hominis, a total of 97 true
positive samples, 849 true negative samples, 10 false positive
samples and 27 false negative samples were identified when
comparing MYCO WELL D-ONE data with that of qPCR.
The sensitivity and specificity for the detection ofM. hominis
infection for the MYCO WELL D-ONE is calculated to be
78.23% and 98.84%, respectively. The positive predictive val-
ue (PPV) and negative predictive value (NPV) of the MYCO
WELL D-ONE to determine Mycoplasma hominis infection
was 90.65% and 96.92%, respectively, with an accuracy of
96.2%.
Antimicrobial screening accuracy
All samples displaying a positive result in the highest concen-
tration of antibiotic (set at the CLSI determined breakpoint
concentrations) were further investigated for antimicrobial re-
sistance utilising the methodology outlined in Beeton et al.
[22]. The guidance included with the MYCO WELL D-
ONE assay stipulates that if the ≥ 105 well is positive, any
positivity in resistance determining wells is invalid and is to
be confirmed by other means. In total, 106 Ureaplasma spp.
isolates were culture purified through serial dilution in spe-
cialist media and screened for antibiotic resistance against one
or more antibiotic, due to positivity displayed in ASTwells of
the MYCO WELL D-ONE. However, these represent all
strains that showed colour change for any antibiotic at 72 h,
and adherence to manufacturer’s guidelines (only consider
those that do not show colour change for the ≥105 bacterial
load and disregard antibiotic resistance that emerges at
timepoints later than the initial positive Mollicute identifica-
tion) greatly reduced the number of false positives identified.
Uncorrected putative resistance included 69 for erythromycin,
25 for josamycin, 30 for tetracycline, 32 for levofloxacin and
23 for moxifloxacin. Of those tested, 94 were excluded due to
a positive ≥ 105 MYCO WELL D-ONE well. By manufac-
turer’s guidelines, these samples would have required confir-
mation following dilution and retesting or by alternative meth-
od. The 12 remaining isolates were predicted to have been
tested at a bacterial load of 104 CCU/mL with various combi-
nations of positive resistance wells; however, antimicrobial
resistance was only seen for 4 of these after 12–24 h additional
incubation and must also be excluded (Fig. 1). Isolates were
screened against one or more antibiotic; 3 against erythromy-
cin, 2 against josamycin, 2 against tetracycline, 3 against
levofloxacin and 4 against moxifloxacin. Of these 8 isolates
determined to be resistant by MYCOWELL D-ONE, two (1
levofloxacin-resistant and 1 tetracycline-resistant) were
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confirmed to be resistant when subjected to CLSI compliant
AST. A further 2 resistant isolates (1 levofloxacin-resistant
and 1 tetracycline-resistant) were discovered following
screening of isolates that possessed a positive > 105CCU/mL
well, indicating that resistance confirmation should be deter-
mined by other means or retested following dilution. In total, 2
levofloxacin-resistant strains (isolates DF99 and KF86) and 2
tetracycline-resistant strains (isolates DF145 and DF28) were
identified to be truly resistant. These isolates were scaled up
and analysed for whole genome sequencing.
For M. hominis, 14 isolates were identified as resistant on
the MYCOWELL D-ONE assay (Fig. 2); however, the assay
does not indicate bacterial load for this species to determine if
they are compliant with CLSI guidelines. However, for 7 of
these isolates, antibiotic resistance was only detected after 13–
28 h after initial organism’s identification and were therefore
excluded as directed by manufacturer’s guidelines. Therefore,
the remaining putative resistant isolates were culture purified
and screened against one or more antibiotics; 4 against
clindamycin, 1 against josamycin, 1 against tetracycline, 2
against levofloxacin and 2 against moxifloxacin. However,
only a single M. hominis isolate was found to be tetracycline
resistant (isolate DF28) following comprehensive confirmato-
ry testing. AST analysis of the remaining M. hominis isolates
identified a further tetracycline-resistant isolate (KM14)
missed by the MYCO WELL D-ONE assay (Fig. 2).
Mechanisms of antimicrobial resistance
determination
Whole genome sequencing of resistant isolates revealed the
genetic elements and somatic mutations conferring the an-
tibiotic resistance to the isolated organism (Table 3). Both
Ureaplasma spp. isola ted and determined to be
levofloxacin resistant (MIC = 4 mg/L) possessed the amino
acid substitution Ser83Leu (serine to leucine substitution)
in the parC gene of the quinolone resistance determining
region (QRDR). The tetracycline-resistant Ureaplasma
spp. isolated both possessed the Tn916 tet(M) conjugated
transposon as did the two tetracycline-resistant M. hominis
isolates. The patient identified as DF28 yielded both a
tet(M)-positive U. parvum strain and a tet(M)-positive M.
hominis strain; however, direct comparison of the genes
found a difference of 24/1920 nucleotides (19 of which
were clustered in close proximity; Fig. 3), indicating
completely separate origins for these strains coincidental
in their infection of the same patient.
Table 1 Sensitivity, specificity,
positive predictive value, negative
predictive value and accuracy for
MYCO WELL D-ONE detection
of Ureaplasma spp.
Detection of
Ureaplasma spp.
Total
sample
number
Sensitivity Specificity Positive
predictive
value
Negative
predictive
value
Accuracy
Overall 983 91.98% 96.44% 95.60% 93.47% 94.40%
Swab 297 92.05% 93.39% 98.29% 88.98% 92.59%
Urine 686 91.94% 99.27% 98.82% 94.91% 96.36%
Male 335 85.71% 99.62% 98.36% 96.35% 96.72%
Female 648 93.14% 93.31% 95.15% 90.61% 93.21%
Relative to qPCR detection ofUreaplasma spp. infection across sample types and genders. TheMYCOWELLD-
ONE was most sensitive for the detection of Ureaplasma spp. infections in females (93.14%), particularly for
swab samples (92.05%). Specificity and accuracy were highest for male (99.62% and 96.72%, respectively) and
urine samples (99.29% and 96.36%, respectively)
Table 2 Sensitivity, specificity,
positive predictive value, negative
predictive value and accuracy for
the MYCO WELL D-ONE de-
tection of Mycoplasma hominis
Detection of
M. hominis
Total sample
number
Sensitivity Specificity Positive
predictive
value
Negative
predictive
value
Accuracy
Overall 983 78.23% 98.84% 90.65% 96.92% 96.24%
Swab 297 78.57% 97.93% 89.80% 95.16% 94.28%
Urine 686 77.46% 99.35% 93.22% 97.45% 97.09%
Male 335 92.86% 99.69% 92.86% 99.69% 99.40%
Female 648 76.36% 98.33% 90.32% 95.32% 94.60%
Relative to qPCR detection ofM. hominis infection across sample types and genders. TheMYCOWELLD-ONE
was most sensitive for the detection of M. hominis infections in males (92.86%). Specificity and accuracy were
highest for male (99.69% and 99.40%, respectively) and urine samples (99.35% and 97.09%, respectively)
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Bacterial load comparison for sample type
It was observed that analysis of Ureaplasma spp. samples
from swabs routinely were identified as having > 105CCU/
mL bacterial loads by MYCO WELL D-ONE identification
wells. Accurate bacterial load quantification by titration in
selective media was used to compare data for different sample
types and genders for both and Ureaplasma spp. and M.
hominis. Given that these dilutions were made from samples
suspended in 10 mL of sterile saline initially, the limit of
detection for the culture titration methodology would be
103CCU/mL. Therefore, where this method failed to grow
isolates, that were detected in parallel either via the single well
inoculation of undiluted urine or detection of colonies on in-
oculated US1 agar, these were recorded to have a bacterial
load of < 103CCU/mL for analysis. Ureaplasma spp. were
detected in 422 samples: 168 swab samples and 254 urine
samples; and for M. hominis, 91 samples were culture-
positive; 48 swab samples and 43 urine samples. Positive
samples were divided into those greater, and those less, than
105CCU/mL (CLSI set limit for accurate AST) and further
sub-categorised by sample type. For Ureaplasma-positive
urine samples, 5.9% (15/254) were > 105 CCU/mL, with
94.1% of samples having Ureaplasma load of < 105CCU/
mL. While for swab samples, 55.9% of Ureaplasma positives
had a bacterial load of > 105 CCU/mL, with the remainder of
positives (44.1%) having Ureaplasma load of < 105CCU/mL
(Fig. 4a). The prevalence of Ureaplasma load of > 105CCU/
mL captured on swab samples is significantly higher than that
of urine samples, for Ureaplasma-positive patients
372 Ureaplasma spp. isolates analysed
by MYCO WELL D-ONE
8 with positive resistance wells & 10
4
 CCU/mL well 
Tetracycline
Resistant
2/372
Tetracycline
Resistant
1/372
Erythromycin
Resistant
0/372
Erythromycin
Resistant
3/372
Levofloxacin
Resistant
3/372
Levofloxacin
Resistant
1/372
Moxifloxacin
Resistant
4/372
Moxifloxacin
Resistant
0/372
Josamycin
Resistant
2/372
Josamycin
Resistant
0/372
Resistance determination using CLSI compliant breakpoint AST
postive at time of initial organism detection
Fig. 1 Flow chart displaying CLSI-compliant AST of Ureaplasma spp.
presumptively identified as resistant by MYCO WELL D-ONE. The
MYCO WELL D-ONE was not found to significantly over-report resis-
tance (p > 0.05; Fisher’s exact test). For isolates that were identified by the
assay as being resistant (without additional incubation post-organism
detection) and at a bacterial load of 104 CCU/mL, one isolate was con-
firmed as resistant to levofloxacin and one isolate to tetracycline. Further
resistant Ureaplasma spp. isolates were found (1 levofloxacin and 1 tet-
racycline) though are omitted from this chart as they were identified as
≥105 CCU/mL by the initial assay screening
100 M. hominis isolates analysed
by MYCO WELL D-ONE
7 with positive resistance wells at time of initial organism detection
Tetracycline
Resistant
1/100
Tetracycline
Resistant
1/100
Clindamycin
Resistant
0/100
Clindamycin
Resistant
4/100
Levofloxacin
Resistant
2/100
Levofloxacin
Resistant
0/100
Moxifloxacin
Resistant
2/100
Moxifloxacin
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0/100
Josamycin
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1/100
Josamycin
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0/100
Resistance determination using CLSI compliant breakpoint AST
* p=0.05
Fig. 2 Flow chart displaying
CLSI-compliant AST of M.
hominis presumptively identified
as resistant by MYCO WELL D-
ONE. The MYCO WELL D-
ONE over-reported clindamycin
resistance (p = 0.05; Fisher’s ex-
act test). One further tetracycline-
resistant M. hominis isolate was
found although it was missed by
the initial assay screening
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(p < 0.0001; Fisher’s exact test). Analysis of M. hominis-pos-
itive samples (Fig. 4b) similarly revealed swabs possess great-
er bacterial loads than M. hominis-positive urine samples. M.
hominis-positive swab samples with a bacterial load of >
105CCU/mL accounted for 40% of total swab-positives (19/
48); 60% of swab-positives had a M. hominis load of <
105CCU/mL (29/48). Whereas 93% of M. hominis-positive
urine samples had a bacterial load < 105 CCU/mL (40/43)
with 7% of positive urines having a M. hominis load of >
105CCU/mL. Fisher’s exact test determined that M. hominis-
positive swab samples have a statistically significant greater
incidence of bacterial loads exceeding 105CCU/mL, when
compared with M. hominis loads of urine-positive samples
(p = 0.0004). Therefore, these assays are much better suited
to urine samples and direct AST evaluation may not be possi-
ble on resuspended swabs without modification of the proto-
col to include additional dilution.
In total, 127 patients provided paired swab and urine sam-
ples, comprised of the following: 122 endocervical swab-
urine pairings from female patients and 5 urethral swab-
urine pairings from male patients, 71 patients were positive
for Ureaplasma spp. and 21 patients M. hominis-positive by
culture titration. The limit of detection for the culture titration
method was 103CCU/mL. Therefore, as above, detection by
culture methods run in parallel not subjected to these limita-
tions are listed as < 103CCU/mL and where no organism was
detected (M. hominis only) the matching negative culture is
shown as 0 (Fig. 5). For Ureaplasma spp. (Fig. 5a), in 38% of
cases, swabs had bacterial loads equal to or 10 times greater
than their urine counterparts. Whereas bacterial loads between
100 and 1000 times higher in swab samples, compared with
their respective urines, were observed in 43.7% of
Ureaplasma-positive samples. Additionally, swabs with
Ureaplasma loads between 103 and 105 and 106–107 times
greater than their urine counterpart samples were observed
in 15.5% and 2.8% of Ureaplasma-positive patients, respec-
tively. A paired t test between paired urine and swab samples
displays swabs have significantly higher bacterial loads than
their respective urine samples (p = 0.0255). For M. hominis-
positive paired patient samples (Fig. 5b), 76.2% (16/21) pos-
sessed swab-positive cultures with bacterial loads equal to, or
greater than, their respective urine samples. For 9.5% (2/21) of
Mycoplasma  721   TCAACACATCGAGGTCAGTCTGAACTTTGCGGAAAAGTTTTCAAAATTGAGTATTCGGAA  780
                  |||||||||||||||| |||||||||||||||||| |||||||||||||| ||| |  ||
Ureaplasma  721   TCAACACATCGAGGTCCGTCTGAACTTTGCGGAAATGTTTTCAAAATTGAATATACAAAA  780
Mycoplasma  781   AAAAGACAGCGTCTTGCATATATACGTCTTTATAGTGGCGTACTGCATTTGCGAGATTCG  840
                  |||||||| ||||||||||||||||| ||||||||||| ||||| ||||| |||||||||
Ureaplasma  781   AAAAGACAACGTCTTGCATATATACGCCTTTATAGTGGAGTACTACATTTACGAGATTCG  840
Mycoplasma  841   GTTAGAATATCGGAAAAGGAAAAAATAAAAATTACAGAAATGTATACTTCAATAAATGGT  900
                  |||||| |||| ||||| |||||||||||| |||||||||||||||||||||||||||||
Ureaplasma  841   GTTAGAGTATCAGAAAAAGAAAAAATAAAAGTTACAGAAATGTATACTTCAATAAATGGT  900
Mycoplasma  901   GAATTATGTAAAATCGATAAGGCTTATTCTGGAGAAATTGTTATTTTGCAAAATGAGTTT  960
                  ||||||||||| || ||||  |||||||||||||||||||||||||||||||||||||||
Ureaplasma  901   GAATTATGTAAGATTGATAGAGCTTATTCTGGAGAAATTGTTATTTTGCAAAATGAGTTT  960
Fig. 3 Nucleotide alignment of the tet(M) gene found in the U. parvum
and M. hominis strains, both co-incidentally isolated from the same pa-
tient. Shown here are nineteen of the twenty-four mismatches in nucleo-
tide identity were clustered in a 180 nucleotide stretch in the middle of the
1920 nucleotide open reading frame, confirming different origins for
these genes and not transfer between these two co-infecting species
Table 3 Details of resistant
isolates Sample number Antibiotic MIC (μg/mL) Resistance mechanism Species
DF99 Levofloxacin 4 Ser83Leu ParC mutation U. parvum
KF86 Levofloxacin 4 Ser83Leu ParC mutation U. parvum
DF28 Tetracycline 128 Tn916 tet(M)a U. parvum
DF145 Tetracycline 32 Tn916 tet(M) U. parvum
DF28 Tetracycline 64 Tn916 tet(M)a M. hominis
KM14 Tetracycline 64 Tn916 tet(M) M. hominis
MIC determined under CLSI-compliant conditions are given alongside the underlying genetic mechanism of
resistance identified by whole genome sequencing analysis
a tet(M) gene sequence from isolated U. parvum and M. hominis strains differed by 24/1920 nucleotides and
therefore originated from different sources
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M. hominis-positive patients with paired samples,M. hominis
could only be recovered from urine samples and was unde-
tectable in the complementary swab sample. Conversely, for a
further 9.5% (2/21) of M. hominis-positive patients with
paired samples, M. hominis was undetectable in the urine
samples, but was recovered from the complementary swab
samples. The remaining sample (1/21), accounting for
4.75% of totalM. hominis-positive paired samples, possessed
a urine sample with a greater bacterial load than its swab
counterpart. Swab samples had M. hominis loads equal to, or
10 times higher, in 42.9% of cases (9/21). Swab samples with
100–1000 times higher, and swab samples with 104–105 times
higher M. hominis loads accounted for 23.8% and 14.3% of
paired samples, respectively. Additionally, 9.5% of paired
swab samples had bacterial loads 106–109 times higher, than
their respective urine samples. However, in two instances,
both comprising 4.5% each of the total M. hominis-positive
paired samples, urine samples had a higher bacterial load than
their swab counterparts, one with a bacterial load 100 times
greater and the other with a load 106 times higher. Finally,
though swab samples more frequently had greater bacterial
loads than their respective urine samples, insufficient matched
samples were available for these differences to achieve a sta-
tistical difference by a paired t test (p = 0.0939).
Time to detection from assay inoculation
A limitation of all non-molecular-based detection and AST
testing assays is the incubation time. Therefore, we analysed
time to first detection for MYCO WELL D-ONE, alongside
the culture titration methodology, was also recorded following
incubation (Fig. 6). Plates were inoculated immediately fol-
lowing receipt of the sample at the hospital in which they were
collected and placed in an incubator in 3 h or less. Samples
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or greater their urine counterparts. However, 2 urine samples detectedM.
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hominis in patients with negative culture results from urine. A universal
trend of lower bacterial load in urine compared to matched swabs was not
always seen for this organism. Statistical analysis of matchedM. hominis-
positive samples failed to achieve significance (p = 0.0939; paired t test)
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a load > 105 CCU/mL. The prevalence of a Ureaplasma load of > 105
CCU/mL captured on swab samples was significantly higher than that of
urine samples, for Ureaplasma positive patients (p ≤ 0.0001; Fisher’s
exact test). b ForM. hominis-positive urine samples, 7% possessed a load
> 105 CCU/mL. Whereas for M. hominis-positive swab samples, 40%
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of > 105 CCU/mL captured on swab samples was significantly higher
than that of urine samples, for M. hominis positive patients (p = 0.0004;
Fisher’s exact test)
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were incubated overnight and read at the earliest convenience
the next day and then at regular intervals until 72 h. For the
culture titration assay, the mean detection time for
Ureaplasma spp. in female patient samples was 28.14 h
post-incubation. Whereas for the MYCO WELL D-ONE,
the mean time to detection for Ureaplasma spp. in female
patients was 27.57 h post-incubation. Themean detection time
for Ureaplasma spp. in male patient samples was 34.09 h for
both assays. Statistical analysis (ANOVA followed by post-
hoc analysis using Bonferroni correction) found no difference
between methods within genders, but that Ureaplasma spp.
was identified significantly faster for female patients
(p < 0.001) than for male patients by either method, and sig-
nificance was removed if swab samples were excluded from
the analysis. For M. hominis, the mean detection time in fe-
male patient samples was 43.26 and 43.00 h for the MYCO
WELL D-ONE and culture titration assay, respectively.
Whereas for the detection of M. hominis in male samples,
the mean time to a positive result was 46.54 h for both assays.
Statistical analysis found no difference for detection time be-
tween genders or methodologies, but that Ureaplasma spp.
was detected a full day faster than M. hominis by any culture
method (p < 0.0001).
Discussion
As the body of evidence associating Ureaplasma spp. andM.
hominis with urogenital pathologies continues to grow, tools
capable of accurately detecting these organisms—particularly
in the low-resource environments of genitourinary medicine
clinics—have the potential to offer clinicians a more compre-
hensive view of the microbial status of symptomatic patients
in the absence of more traditional sexual health pathogens
(chlamydia, gonorrhoea, M. genitalium, etc.). Additionally,
the inherent antibiotic-resistant nature of these organisms in-
creases the risk of the empirical treatment approaches
employed to treat symptomatic non-gonococcal urogenital in-
fections failing. Therefore, systems capable of reliably detect-
ing and concurrently screening these organisms against a pan-
el of commonly prescribed antimicrobials will be valuable in
instances to perform proper epidemiological evaluations of
the pathogenic potential of these organisms. Additionally,
the added information provided by these assays will allow
screening for resistance to the subset of antimicrobials that
are effective to treat these infections.
For the detection of Ureaplasma spp., the MYCO WELL
D-ONE has overall sensitivity and specificity of 91.98% and
96.44%, compared with multiplex qPCR. This is consistent
with a publication comparing PCR with Mycotest
(Bioprepare), showing sensitivity and specificity of 92.4%
and 93.8%, respectively [40]. However, wide-ranging sensi-
tivities and specificities for culture-based Ureaplasma detec-
tion methods versus PCR have been published. For example,
the sensitivity of the Mycoplasma IST2 (Biomerieux) com-
pared with a commercially available PCR (Anyplex II;
Seegene) was only 44.9%, with a specificity of 87.9% [41].
A previous publication by Favalli et al. has compared the
detection of the MYCO WELL D-ONE to the commercial
detection kit Anyplex II [42]. These authors were able to eval-
uate the extended capacity of the kit to detect non-Mollicutes
and found excellent concordance in detecting 33/39
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Fig. 6 Bar and whisker graphs
displaying the min-max detection
times forUreaplasma spp. andM.
hominis. Samples from males and
females are examined separately
comparing the MYCO WELL D-
ONE assay to culture titration as-
say in specialist media. Mean
values are represented by + sym-
bol. Time to detection of
Ureaplasma spp. in female sam-
ples was 28.14 h (culture titration)
and 27.57 (MYCO WELL D-
ONE) (a) and 34.09 h in males
was for both assays (b). Time to
detection of M. hominis in fe-
males was 43.26 and 43 h for
MYCO WELL D-ONE and cul-
ture titration, respectively (c), and
46.25 h in male samples (d).
There was no significant differ-
ence in time to detection between
assays
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Gardnerella vaginalis and 3/3 Trichomonas vaginalis infec-
tions. They found slightly lower Mycoplasma hominis values
(sensitivity 71.4%; sensitivity 90.7%) and significantly lower
values forUreaplasma spp. (48.98% and 93.4% for sensitivity
and specificity respectively, compared to ours at 91.98% and
96.44%). These relatively low values were due to 4 positives
on MYCO WELL D-ONE not detected by Anyplex II, and
demonstrates the limitations of a small sample number (N =
110) and comparison to only one detection method that was
neither quantitative nor regarded as a clinical diagnostic gold
standard. We adopted a novel method of confirming colour
changed wells by direct subculture and qPCR, which routinely
supported the highly sensitive detection of the MYCOWELL
D-ONE when load was too low to be detected by our other
methods. This highlights the importance of confirming posi-
tive cultures with molecular methods to properly categorise
ostensibly false positive culture results. For the detection ofM.
hominis, the overall sensitivity and specificity was 78.23%
and 98.84%, respectively. As a limitation to all molecular
detection methods, Favalli et al. were also unable to evaluate
the antimicrobial susceptibility screening function of the
MYCO WELL D-ONE assay. When comparing PCR with
culture, Petrikkos et al. found a 29.6% reduction in detection
sensitivity between Ureaplasma spp. and M. hominis with
sensitivity declining from 92.4% for Ureaplasma spp. to
62.8% for M. hominis. Similarly, the sensitivity of the
MYCO WELL D-ONE declined by 13.75%, from 91.98%
for the detection of Ureaplasma spp. to 78.23% for the detec-
tion ofM. hominis. Petrikkos and colleagues also reported that
the specificity forM. hominis detection remained in relatively
high concordance with molecular methods, at 98.8%.
Comparable results are presented here with M. hominis spec-
ificity being calculated to be 98.84%. Further support for the
notion of culture being less sensitive for the detection of M.
hominis, than it is for the detection of Ureaplasma spp., is
offered by Abele-Horn et al.’s sensitivity values for
Ureaplasma spp. and M. hominis detection at 91% and 84%,
respectively [43]. The disparity between sensitivity for the
culture-based detection of Ureaplasma spp. and M. hominis
has not been explained elsewhere, though it has been deter-
mined that M. hominis are harder to recover by culture-based
means than Ureaplasma spp.; recovery rate of Ureaplasma
spp. is 95%, compared with a recovery rate of 60% for M.
hominis [44]. So, it may simply be that through using culture-
based assays, M. hominis is harder to recover than
Ureaplasma spp. and is perhaps an indication of their more
fastidious nature. Across all sample types, the specificity ofM.
hominis detection by the MYCO WELL D-ONE was consis-
tently > 97%, demonstrating that the assay had an exception-
ally low false positive rate.
The performance of the semi-quantitative well for
Ureaplasma spp. was unable to be assessed, given an error
in our study design. The primary aim of this well is to quantify
the Ureaplasma spp. inoculum as CLSI-compliant or not (≤
104 CCU/mL) to minimise the identification false resistance,
as it has been previously demonstrated that a failure to cor-
rectly quantify Ureaplasma concentrations led to an over-
reporting of resistance [22]. Unfortunately, we only recorded
the results for these wells at 72 h and were unable to retro-
spectively re-analyse the data as we had done for the antibiotic
susceptibility data where time to detection and time of antibi-
otic well readings were separately recorded. Given that we did
not record the times for the Ureaplasma spp. bacterial load
wells, it would be unfair to analyse the accuracy of these
results against definitive methods. We tested whether
prolonged incubation led to artificial errors by re-examining
25 Ureaplasma isolates at > 105 CCU and < 105 CCU and
found that readings at first colour change (16–18 h) were
completely accurate for both antimicrobial resistance and bac-
terial load, but over-estimate for bacterial load occurred for 8
isolates at < 105 CCU and false antimicrobial resistance was
found for 3 isolates at 72 h as opposed to accurate readings at
first organism identification (16–24 h) (data not shown).
Therefore, it is critical that these wells not be allowed to
over-incubate.
Levofloxacin resistance for Ureaplasma spp. was 0.54%,
considerably lower than rates published in other studies. In
Minnesota, 250 clinically isolated Ureaplasma spp. subjected
to MIC testing determined a levofloxacin resistance rate of
6.4% and 5.2% forU. parvum andU. urealyticum, respective-
ly [45]. Molecular characterisation of the isolates in the
Fernandez et al. study revealed 93% of levofloxacin-resistant
Ureaplasma spp. to possess the parC quinolone-associated
resistance mutation, Ser83Leu. Similarly, sequencing of the
two levofloxacin-resistant isolates identified here confirmed
a Ser83Leu mutation in the parC gene. This Ser83Leu
parC gene mutation is the most prevalent levofloxacin re-
sistance mechanism identified in Ureaplasma spp. isolates,
accounting for up to 87% of fluoroquinolone resistance
[45–48]. Though comparatively low, the levofloxacin resis-
tance rate reported here is not unusual, being concordant in
US and French studies: 1.4% and 1.2%, respectively [49,
50]. Conversely, Song et al. reported levofloxacin resistance
for Ureaplasma spp. in China to be 75% and the most com-
mon mechanism of resistance to be mostly conferred by the
Ser83Leu parC mutation [51]. They attributed the high re-
s is tance ra tes to widespread and genera l use of
fluoroquinolones in China. Beeton et al. determined 2/130
isolates to have relative resistance to ciprofloxacin in sam-
ples from England in Wales, but to have an MIC = 2 mg/L
for levofloxacin and therefore considered to be below the
breakpoint, despite both having the Ser93Leu parC muta-
tion [52]. This coupled with our equivalent findings of 2/
424 isolates having intermediate resistance (MIC = 4 mg/L
levofloxacin) confirm extremely low fluoroquinolone resis-
tance for Ureaplasma spp. in Wales.
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Tetracycline resistance in Ureaplasma spp. was 0.54%,
also particularly low.Molecular characterisation of the isolates
revealed that both harboured the Tn916 tet(M) conjugated
transposon, the only identified mechanism by which
Ureaplasma spp. possess tetracycline resistance [53].
Tetracycline resistance rates for Ureaplasma spp. typically
range between 0 and 14% globally: 0%, Croatia [54]; 1%,
China [55]; 2%, Italy [56]; 6%, Hungary [57]; 14%, Turkey
[58]. Though tetracycline resistance rates as high as 34% have
been published following CLSI-compliant AST of
Ureaplasma spp. isolates in the USA [46]. However, more
recently, Valentine-King and Brown published a 1.4% tetra-
cycline resistance rate for Ureaplasma spp. in Florida, USA
[49]. Comparatively, screening for tetracycline resistance in
Ureaplasma spp. populations in Wales and England has con-
sistently reported rates of 2% [22, 52]. The findings of this
study show that tet(M) prevalence in Ureaplasma spp. popu-
lations throughout Wales have not appreciably increased.
Likewise, a 6-year analysis of Ureaplasma spp. isolates in
France over a 6-year period (2010–2015) did not note any
increase in tet(M) prevalence, ~ 7.5% [50]. But, previous
French data (1999–2002) determined Ureaplasma spp. tetra-
cycline resistance rates to be at 2.2% [59]. Therefore, whilst
no significant change was seen in the most recent 6-year as-
sessment, there has been an overall rise in tetracycline resis-
tance over the last 20 years. This highlights the need for con-
tinued antibiotic resistance surveillance for Ureaplasma spp.
to track such changes in geographically distinct locations, es-
pecially as tetracycline is prescribed as a first-line therapy in
the treatment of adult urogenital Ureaplasma spp. infection.
For M. hominis, 2 tetracycline-resistant isolates were identi-
fied giving a relatively low resistance rate of 2%. However,
reported resistance forM. hominis varies greatly, ranging from
0 to 100% [60–62]. Though typically, resistance rates are sit-
uated between 10 and 40% of M. hominis, globally [63, 64].
Both isolates determined to be tetracycline-resistant harboured
the Tn916 tet(M) gene. LikeUreaplasma spp., this is the most
described resistance mechanism for tetracycline resistance in
M. hominis. However, it is important to note that while a
tet(M)-positive tetracycline-resistant Ureaplasma parvum
and M. hominis were both isolated from the same patient
(DF28), sequence identity of the genes was only
1896/1920 bp, indicating they had acquired the gene indepen-
dently. Whilst the rate of tetracycline resistance for South
WalesM. hominis is relatively low, examples of rates between
0 and 5% are not uncommon [65, 66]. Analysis of the MYCO
WELL D-ONE showed good concordance with traditional
methods of susceptibility testing, with only a minor number
of false identification of levofloxacin and moxifloxacin resis-
tance in Ureaplasma spp., and clindamycin resistance for M.
hominis. A note of caution needs to be emphasized that the
antimicrobial resistance does give much higher false positive
rates if not recorded concurrently at the time the species
identification wells first turn red. However, with the differen-
tial time to positivity for the two separate bacterial species
(Fig. 6), this can become quite complicated. Irrespective, it
is always important that any putative resistant results should
always have an accurate MIC determined for confirmation
using CLSI compliant methodologies, and any commercial
assay should only be used as an initial screening method for
controlled epidemiological studies.
For culture-based assays to successfully and concurrently
detect genital mycoplasmas and screen for antibiotic resis-
tance, CLSI-compliant bacterial titres are required (<
105CCU/mL) [21]. Accordingly, bacterial titres between sam-
ple types were investigated, revealing swabs to consistently
produce titres > 105CCU/mL for both Ureaplasma spp. and
M. hominis, following resuspension in 10 mL of saline
(Fig. 4), which was particularly striking for matched urine/
swab sample analysis (Fig. 5). The comparable sensitivities
and specificities for the detection of Ureaplasma spp. and M.
hominis (Tables 1 and 2) between sample types coupled with
the differences in bacterial load suggest that urine samples are
the preferred option for concurrent cultured-based detection
and CLSI-complaint AST of genital mycoplasmas.
Whilst the designation ofUreaplasma spp. andM. hominis
as pathogen, commensal or pathobiont remains variable, tools
that facilitate their identification may aid in resolving such
controversy. The MYCOWELL D-ONE displays high sensi-
tivity and specificity values for the detection of Ureaplasma
spp., with the results being comparable to the widely-used
Abbott real-time PCR for the detection ofC. trachomatis (sen-
sit ivi ty, 92,4%; specifici ty 99.2%) [67]. Though
MYCOWELL D-ONE M. hominis sensitivity decreased
slightly; this is seemingly a universal difference in the ability
of culture-based methods to recover these organisms. This
does not negate the effectiveness of this assay to detect M.
hominis infection, evidenced by the high values seen across
specificity, PPV, NPVand accuracy. Whilst qPCR remains the
preferred detection method due to its increased sensitivity and
ability to speciate Ureaplasma infections, the current
European guidelines state routine screening for these organ-
isms is undesirable in lieu of substantiating that the treatment
of asymptomatic genital mycoplasma infection is beneficial.
Therefore, the sample numbers required to facilitate econom-
ically viable high-throughput molecular testing for genital my-
coplasmas, as is currently performed for STIs such as C.
trachomatis, are not investigated. In instances of symptomatic
non-gonococcal urogenital pathologies, assays such as the
MYCO WELL D-ONE provide a simple, economic and ac-
curate method for determining the presence of Ureaplasma
spp. or M. hominis in the urogenital tract. Accordingly, it
allows clinicians a more comprehensive view of the urogenital
microbiome underlying certain pathologies, further elucidat-
ing the aetiology of non-gonococcal urethritis, facilitating
better-informed guided therapy. This may help to alleviate
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the concerns of empirical treatments fuelling the generation of
multi-drug resistant urogenital pathogens [68] and avoid inap-
propriate empirical treatment for NGU in cohorts where
Ureaplasma spp. may be the causative agent [69]. The geo-
graphic variability of antimicrobial resistance rates for these
organisms highlights the need to continually survey popula-
tions for trends in resistance. Whilst the MYCO WELL D-
ONE offers a useful presumptive screening method, the need
to affirm the result through CLSI-compliant means, or deter-
mination of underlying molecular methods of antimicrobial
resistance, to prevent the over-reporting of antimicrobial resis-
tance is essential [20, 22].
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